Search

Search Results

• PROGNOSTIC SIGNIFICANCE OF TRANSCRIPT-TYPE BCR/ABL1 IN CHRONIC MYELOID LEUKEMIA

  matteo molica, elisabetta abruzzese, massimo breccia

  e2020062

  2020-09-12

  https://doi.org/10.4084/mjhid.2020.062

  4113

  PDF: 1668

  HTML: 813

• ANTIFUNGAL THERAPY IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS

  Alessandro Busca, Livio Pagano

  e2016039

  2016-09-01

  https://doi.org/10.4084/mjhid.2016.039

  4855

  PDF: 1602

  HTML: 2263

  Untitled: 251

  Untitled: 264

  Untitled: 284

  Untitled: 235

  Untitled: 253

• Immune thrombocytopenic purpura cases following COVID-19 vaccination.

  Annalisa Condorelli, Uros Markovic, Roberta Sciortino, Mary Ann Di Giorgio, Daniela Nicolosi, Gaetano Giuffrida

  e2021047

  2021-06-28

  https://doi.org/10.4084/MJHID.2021.047

  1169

  PDF: 472

  HTML: 344

• HYDROXYCARBAMINE: FROM AN OLD DRUG USED IN MALIGNANT HEMOPATHIES TO A CURRENT STANDARD IN SICKLE CELL DISEASE

  Giovanna Cannas, Solene Poutrel, Xavier Thomas

  e2017015

  2017-02-15

  https://doi.org/10.4084/mjhid.2017.015

  4035

  PDF: 1215

  HTML: 1844

• COMPARISON OF INFECTIOUS COMPLICATIONS IN PATIENTS RECEIVING HIGH-DOSE CYCLOPHOSPHAMIDE AS GVHD AFTER TRANSPLANTATION FROM A 9/10 HLA-MATCHED UNRELATED DONOR WITH STANDARD GVHD PROPHYLAXIS AFTER TRANSPLANT FROM A FULL MATCHING DONOR Infection With PTCy Versus Standard GvHD Prophylaxis

  Selim SAYIN

  e2024016

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.016

  1523

  PDF: 1370

  HTML: 112

• BETTER OUTCOME OF HIGH-DOSE CEFTAZIDIME IN HEMATO – ONCOLOGICAL PATIENTS WITH INFECTIONS CAUSED BY EXTENSIVELY DRUG-RESISTANT PSEUDOMONAS AERUGINOSA

  Alzbeta Zavrelova, Jakub Radocha, Pavla Paterova, Pavel Zak, Benjamin Visek, Martin Sima

  e2023001

  2022-12-31

  https://doi.org/10.4084/MJHID.2023.001

  1326

  PDF: 1156

  HTML: 510

• BCR SIGNALING INHIBITORS: AN OVERVIEW OF TOXICITIES ASSOCIATED WITH IBRUTINIB AND IDELALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

  Lorenzo Falchi, Jessica M Baron, Carrie Anne Orlikowski, Alessandra Ferrajoli

  e2016011

  2016-02-10

  https://doi.org/10.4084/mjhid.2016.011

  4421

  PDF: 1528

  HTML: 3725

• Guest Editor: Pellegrino Musto HOW FIRST-LINE THERAPY IS CHANGING IN NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS.

  Daniele Derudas

  e2025025

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.025

  1687

  PDF: 1431

  HTML: 166

• HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THALASSEMIA AND SICKLE CELL DISEASE: EXPERIENCE OF MEDITERRANEAN INSTITUTE OF HEMATOLOGY IN A MULTI-ETHNIC POPULATION.

  Marco Marziali, Antonella Isgrò, Javid Gaziev, Guido Lucarelli

  e2009027

  2009-12-26

  1779

  PDF: 744

  HTML: 2975

• LYMPHOCYTES IN PATIENTS WITH CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION EXHIBITED ELEVATED PD-1/PD-L1 EXPRESSION AND A PREVAILING TH2 IMMUNE RESPONSE. EPSTEIN-BARR VIRUS INFECTION EXHIBITED ELEVATED PD-1/PD-L1

  kang sun

  e2024037

  2024-04-30

  https://doi.org/10.4084/MJHID.2024.037

  2998

  PDF: 1140

  HTML: 128

• VASCULAR ENDOTHELIAL GROWTH FACTOR IN CHILDREN WITH THALASSEMIA MAJOR PDF

  sameh samir fahmey, Hassan Naguib, sanna Abdelshafy, rasha Alashry

  e2013044

  2013-06-05

  https://doi.org/10.4084/mjhid.2013.044

  1389

  PDF: 898

  HTML: 1130

  Figure 1 the correlation between frequency of blood transfusion and serum vascular endothelial growth factor (VEGF).: 207